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There are common aspects and mechanisms between different types of autoimmune 
diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders 
(NMOSDs), and autoimmune encephalitis (AE) as well as paraneoplastic inflammatory 
disorders of the central nervous system. To our present knowledge, depending on 
the disease, T and B cells as well as antibodies contribute to various aspects of the 
pathogenesis. Possibly the events leading to the breaking of tolerance between the 
different diseases are of great similarity and so far, only partially understood. Beside 
endogenous factors (genetics, genomics, epigenetics, malignancy) also exogenous fac-
tors (vitamin D, sun light exposure, smoking, gut microbiome, viral infections) contribute 
to susceptibility in such diseases. What differs between these disorders are the target 
molecules of the immune attack. For T cells, these target molecules are presented on 
major histocompatibility complex (MHC) molecules as MHC-bound ligands. B cells have 
an important role by amplifying the immune response of T cells by capturing antigen with 
their surface immunoglobulin and presenting it to T cells. Antibodies secreted by plasma 
cells that have differentiated from B  cells are highly structure specific and can have 
important effector functions leading to functional impairment or/and lesion evolvement. 
In MS, the target molecules are mainly myelin- and neuron/axon-derived proteins; in 
NMOSD, mainly aquaporin-4 expressed on astrocytes; and in AE, various proteins that 
are expressed by neurons and axons.
Keywords: T  cell, B  cell, major histocompatibility complex, human leukocyte antigen, multiple sclerosis, 
neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic disease
inTRODUCTiOn
Various autoimmune and paraneoplastic disorders of the central nervous system (CNS) share many 
immunological similarities. In these disorders, immunologic tolerance to self-antigens is broken 
(1). This failure can be on the T  cell as well as on the B  cell side or on both sides. The reasons 
why tolerance is broken in autoimmune diseases are multiple and can differ from paraneoplastic 
diseases (2). In autoimmune disease, the initial trigger that leads to breaking of tolerance is not as 
well understood (3). Possibly viral, bacterial and fungal antigens that share antigenic properties 
with self-antigens can result in activation of T or/and B cells that also recognize self-antigens in 
the CNS (4). Another possibility could be that in certain autoimmune-prone individuals compared 
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with non-autoimmune-prone individuals, the T and B cell rep-
ertoires contain higher quantities of cells with a high avidity for 
self-antigens that can be activated and can gain access to the CNS 
in which they find relevant target structures. Such a scenario has 
been underscored in rodent models of CNS autoimmune diseases 
(5). In paraneoplastic diseases of the CNS, epitopes from a neo-
plasm are exposed on antigen-presenting cells to T cells which 
subsequently also recognize an epitope of similar structural 
appearance in the CNS (6).
Importantly, the T and B cell epitopes can differ depending 
on antigen processing in autoimmune disease and possibly also 
paraneoplastic disease (7, 8). In many autoimmune and paraneo-
plastic diseases of the CNS, the B  cell response is much better 
characterized as compared with the T cell response (1, 9). T cell 
help is required for differentiation of B cells into plasma cells and 
affinity maturation of antibodies (10, 11). There are also B cells 
which do not require T cell help in autoimmunity, but these do 
not seem to be of major importance in CNS autoimmunity and 
CNS paraneoplastic diseases as far as one knows to date (12–14).
enDOGenOUS FACTORS
Endogenous factors that contribute to the induction of autoim-
munity or paraneoplastic diseases are multiple. First, genetics is of 
paramount importance. Most autoimmune diseases are complex 
genetic diseases (15). This means that certain allelic variants of 
genes predispose to autoimmunity. There are also few examples of 
autoimmune diseases in which single mutated genes predispose 
to autoimmunity (16). For CNS-directed autoimmune diseases, 
no confirmed single genes with mutations have been discovered 
so far. Much work has been done in elucidating genes that con-
tribute to the complex genetic etiologies (17). Most probably also 
in CNS immune-directed disorders with paraneoplastic origins, 
complex genetics are of importance. RNA expression levels have 
been shown to be altered in autoimmune and paraneoplastic 
diseases of the CNS (18–20). Tissue with altered RNA expression 
levels as compared with healthy tissue might predispose to auto-
immunity and paraneoplastic diseases (21). There is increased 
understanding that epigenetics is very crucial in susceptibility to 
autoimmunity and paraneoplastic disorders (22, 23). Much will 
be learned in the next years regarding epigenetic regulation of 
immunity and autoimmunity.
eXOGenOUS FACTORS
Much has been discovered regarding exogenous factors that affect 
autoimmune diseases of the CNS. These exogenous factors coop-
erate with endogenous factors in susceptibility to autoimmune 
diseases of the CNS (24). Low vitamin D levels as well as low sun 
light exposure have been shown to contribute to susceptibility 
to multiple sclerosis (MS) also independently of other factors 
(25–27). So far, the influence of vitamin D and sun light exposure 
has not been defined to the same degree for neuromyelitis optica 
spectrum disorders (NMOSDs) and autoimmune encephalitis 
(AE) (28). Smoking has a negative influence on MS (29, 30). This 
influence is controlled to some degree by human leukocyte anti-
gen (HLA) genes underscoring that HLA-presented autoantigens 
are possibly modified and promote a more vigorous autoimmune 
response (29). It has been shown that in MS there is a change of 
the gut microbiome (31, 32). Also in NMOSD, changes in the 
gut microbiome have been observed with overrepresentation 
of Clostridium perfringens (33). In experimental autoimmune 
encephalomyelitis (EAE), it has been experimentally proven that 
the gut microbiome contributes to disease susceptibility (34). So 
far, in most types of diseases it is not well defined what specific 
bacteria of the gut microbiome drive autoimmune disease. It has 
been shown that Epstein–Barr virus (EBV) infection has an influ-
ence on MS susceptibility (35, 36). The influence is mainly medi-
ated in childhood and most likely affects the T  cell repertoire. 
Even though a direct role of EBV infection in MS lesion develop-
ment was claimed, this could not be confirmed (37). Also, salt 
intake has been shown to influence EAE susceptibility (38). So far, 
it is not clear if levels of salt intake are influencing susceptibility 
or disease course in MS (39). The elucidation of the influence of 
nutritional factors in various autoimmune diseases of the CNS is 
presently investigated in more detail. Regarding paraneoplastic 
diseases, no such influence has been elucidated so far.
MAJOR HiSTOCOMPATiBiLiTY COMPLeX 
(MHC)/HLA HAPLOTYPeS
Most autoimmune diseases are associated with certain MHC/
HLA haplotypes (40). Such associations also exist for some para-
neoplastic diseases such as paraneoplastic pemphigus (41). So far, 
influences of HLA haplotypes on paraneoplastic diseases have not 
been investigated in much detail. The reason for the haplotype 
preferences of specific autoimmune diseases is not known.
The most likely scenario for influences of HLA haplotypes 
on autoimmune diseases indicates that during early tolerance 
development certain HLA haplotypes select for a T cell repertoire 
that can be self-biased to certain autoantigens and certain organs 
(42–44). In the emergence of tolerance, there is selection of a 
broad range of T cell receptors (TCRs) on various self-antigens. 
In a first step, only T cells are selected that recognize self MHC-
peptide complexes (45–47). In the next step, T cells with TCRs 
with a too high affinity for such complexes are deleted from the 
repertoire (48, 49). MHC displayed peptide repertoires influence 
positive and negative selection (50). Based on the expressed 
HLA haplotypes, the predetermined T cell repertoire differs in 
individuals (51, 52). The TCR repertoire has a bias depending on 
the HLA haplotype in avidity for certain self-antigens (53, 54).
In MHC congenic rat strains, we have shown that there is 
an autoantigen preference that can result, depending on the 
expressed MHC alleles, in disease susceptibility or protection 
from certain diseases (5, 55). Interestingly with increasing com-
plexity of the disease driving autoantigen, the MHC haplotype-
dependent effects alleviate (56, 57). Also, we have shown that the 
amount of autoantigen that leads to disease induction can differ 
between different MHC haplotypes (5, 58). This means that in 
one MHC haplotype minute amounts of antigens are sufficient 
to induce severe disease, while in others much higher amounts 
would be necessary. These findings underscore the influence 
of the antigenic load in context with genetic factors. It has 
been shown that depending on the expressed MHC haplotype, 
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the cytokine preference of the selected T  cell repertoire differs 
(44, 59). Recently in an experimental model of rheumatoid arthri-
tis (RA), it has been shown that MHC alleles that drive disease 
are associated with a T helper cell type 1 (Th1) response with 
secretion of interferon-gamma (IFN-γ) (60). By contrast, protec-
tive MHC alleles promoted an interleukin-17 T helper (Th17) 
cell response. Such a predetermination of cytokine responses 
to disease-inducing factors is potentially also shaped early in 
tolerance development and can also contribute to the finding 
that certain HLA haplotypes predispose to certain autoimmune 
diseases while others protect from disease.
neOAnTiGenS
Tolerance can be broken by presentation of neoantigens on MHC 
molecules to T  cells recognizing antigens that share structural 
similarities to self-molecules (61). Recently, it has been shown 
that neoantigens for presentation on MHC I molecules can be 
generated by fusion of different fragments of degraded proteins 
during antigen processing (62). In addition, endogenous neoanti-
gens could evolve by mutation or translational defects. So far, the 
experimental data that such novel antigens could play a role in the 
induction or maintenance of autoimmune disease of the CNS are 
still lacking but an interesting avenue of future research efforts.
Posttranslational modifications of antigens can also lead to 
induction of autoimmunity (63). This has been shown for RA 
in which citrullinated epitopes have been shown to be disease 
inducing (64, 65). Also for MS, a role for citrullination has been 
proposed but so far there is no proof for the relevance in the 
experimental or human setting (66, 67). Possibly transpeptidation 
could be of importance as has been shown in a model of diabetes 
(68). Changes in glycosylation can affect induction of autoim-
munity (69). Also, other types of posttranslational modifications 
could be of great relevance but have not been investigated in 
much detail regarding CNS autoimmunity or CNS paraneoplastic 
diseases. We have shown that even the conformational state of an 
autoantigen can have different consequences on disease induc-
tion capacity (8). Therefore, different conformations of an antigen 
can be seen be the immune system in a “neoantigenic” fashion 
and lead to autoimmunity (70).
SPeCiFiC DiSeASeS
Multiple Sclerosis
In MS, the target of the autoimmune response, which seems to be 
predominantly T cell driven, is mainly directed against proteins 
of the myelin sheath which is produced by oligodendrocytes (1) 
(Table 1). Myelin basic protein (MBP) is thought to be the major 
autoantigen which is involved (71, 72). Many researchers have 
addressed this topic and found additional myelin proteins that 
can be the target of the autoimmune response (1). There are strong 
indications that the humoral immune response is important as 
well (73). Nevertheless, the exact autoantigens driving this B cell 
response are not known to date in detail. Myelin oligodendrocyte 
glycoprotein (MOG) is a model antigen which has been shown 
to be of major importance driving the B cells response in rodent 
and primate models (74). This protein, which is expressed on 
the outer surface of the myelin sheath, seems to be involved in 
children but not to the same extent in older people with MS in 
the immune pathogenesis of MS (75). Especially young children 
with MS with an age under 10  years have a robust anti-MOG 
antibody response. This finding underscores that potentially early 
in life immunological events are taking place that predispose to 
development of MS later in life. CNS lesions of MS patients show 
antibody-dependent complement destruction underscoring the 
importance of the antibody response in MS (73). Moreover, pro-
teins expressed on neurons and axons have also been discussed 
to be targets of the immune response in patients with MS based 
on work in EAE (76). Recently, in patients with MS, we have 
shown that peptides can be eluted from MHC molecules from 
CNS tissue that are recognized by T cells secreting IFN-γ (Th1) 
(72, 77). Importantly, the increased immune reactivity against 
such peptides is observed in patients with active MS, i.e., in patients 
with MS who have an acute bout- or/and contrast-enhancing 
lesions in the CNS indicating active inflammation. This finding 
underscores that the adaptive immune response against CNS-
derived autoantigens is of significance in MS. Importantly, the 
T cell reactivity is directed not only against MBP but additional 
autoantigens and differs between individuals.
neuromyelitis Optica Spectrum Disorders
In NMOSD, it has been demonstrated that the immune response 
is targeting aquaporin-4 (AQP4), a water channel protein on 
astrocytes (127) (Table 1). Certain cases of NMOSD are associ-
ated with an immune response against MOG (128). In both types, 
antibody-dependent tissue destruction is of major importance 
(96). The role of T cells is presently analyzed in more detail (94). 
In rodent models, it has been delineated that direct injection of 
anti-AQP4 antibody in the CNS can lead to severe pathology 
without the presence of T cells (129). Also, antibody-dependent 
destruction of tissue by complement seems to be of paramount 
importance and dependent on the antigen conformation and the 
presence of antibodies (130). It is not excluded that also addi-
tional target molecules will be discovered, which are associated 
with seronegative forms of NMOSD in the future.
Autoimmune encephalitis
There are a high number of diseases in which the autoimmune 
response is directed against neuronal antigens (1) (Table 1). The 
target molecules can be localized intracellular or extracellular 
(9, 98). Some of the intracellular antigens are nuclear proteins. 
Most of the diseases in which the immune response is directed 
against intracellular neuronal targets are of paraneoplastic 
origin. Mainly, CD8+ T cells, which are MHC I restricted, are 
involved in the immune pathogenesis of these types of AE (131). 
In affected patients, most important is the search for the underly-
ing neoplasm and its treatment. In addition, immunotherapy is 
meaningful (132).
In diseases in which the target structures are exposed extracel-
lular as membrane proteins, more diseases are of autoimmune 
origin and less paraneoplastic. A prototype is the anti-N-methyl-
d-aspartate receptor (NMDA) receptor encephalitis in which the 
NMDA receptor is the target molecule of the immune response 
TABLe 1 | Human diseases and autoantigens, main cellular expression, and cellular compartment of expression as well as involved immune responses 
as presently known.
Disease (Auto)antigen Target cell Main cellular localization established role of
T cells Antibodies Complement
MS Actin U C, CS, ES + (72) ND ND
MS Alpha-synuclein N U, not P + (72) ND ND
MS CNPase, 2′,3′-cyclic-nucleotide 3′-phosphodiesterase O, N ES, CS, N + (78) + (79) ND
MS GFAP, glial fibrillary acidic protein A C, CS + (72) − (80) ND
MS Glutamate dehydrogenase U M + (72) ND ND
MS MAG, myelin-associated glycoprotein O PM + (81) + (81) ND
MS MBP, myelin basic protein O PM, C, N + (72, 82, 83) + (79) ND
MS MOBP, myelin-associated oligodendrocyte basic protein O PM + (84) + (79) ND
MS MOG, myelin oligodendrocyte glycoprotein O PM + (85, 86) + (87) + (88)
MS Neurofilament-3 N CS, C, N + (72) + (89) ND
MS PLP, proteolipid protein O PM + (90) + (79) ND
MS S100β, S100 calcium-binding protein B A E, C, N + (91) − (80) ND
MS Survivin U C, CS, N + (72) ND ND
MS Transaldolase U E, C, N + (92) + (93) ND
NMOSD AQP4, aquaporin-4 A PM + (94) + (95) + (96)
NMOSD MOG, myelin oligodendrocyte glycoprotein O PM ND + (97) + (88)
AE AK5, adenylate kinase 5 N C, ES ND + (98) ND
AE AMPAR, glutamate ionotropic receptor AMPA type N PM ND + (99) ND
AE Amphiphysin N PM, C, CS, GA ND + (100) ND
AE CASPR2, contactin associated protein-like 2 N PM, E, GA ND + (101) ND
AE CRMP5, dihydropyrimidinase-like 5 N C ND + (102) ND
AE DNER (Tr), delta-/notch-like EGF repeat containing N PM, E ND + (103) ND
AE Dopamine receptor D2 N PM, C ND + (104) ND
AE DPPX, dipeptidyl peptidase N ES, L, PM, V ND + (105) ND
AE GABAaR, gamma-aminobutyric acid type A receptor N PM ND + (106) ND
AE GABAbR, gamma-aminobutyric acid type B receptor N PM ND + (107) ND
AE GAD65, glutamate decarboxylase 2 N C, PM + (108) + (109) − (108)
AE GlyR, glycine receptor N PM ND + (110) ND
AE Hu, ELAV-like RNA-binding protein 4 N C, N + (108, 111) + (112) − (108)
AE IgLON5, IgLON family member 5 N ES, PM ND + (113) ND
AE LGI1, leucine-rich glioma-inactivated 1 N ES, PM + (108) + (114, 115) + (108)
AE Ma1, paraneoplastic Ma antigen 1 N N ND + (116) ND
AE Ma2, paraneoplastic Ma antigen 2 N N + (108) + (117) − (108)
AE mGluR1, glutamate metabotropic receptor 1 N PM, C ND + (118) ND
AE mGluR5, glutamate metabotropic receptor 5 N ES, PM ND + (119) ND
AE Neurexin-3a N PM ND + (120) ND
AE NMDAR, glutamate ionotropic receptor NMDA type N PM + (108) + (121) − (108)
AE P/Q type VGCC, calcium voltage-gated channel N PM ND + (122) ND
AE Ri, NOVA alternative splicing regulator 1 N N ND + (123) ND
AE Yo, cerebellar degeneration-related protein 2 N N ND + (124, 125) ND
AE Zic4, Zic family member 4 N N ND + (126) ND
A, astrocytes; AE, autoimmune encephalitis; C, cytosol; CS, cytoskeleton; E, endosome; ES, extracellular space; GA, Golgi apparatus; L, lysosome; M, mitochondria; MS, multiple 
sclerosis; N, neurons; N, nucleus; ND, not determined; NMOSD, neuromyelitis optica spectrum disorder; O, oligodendrocytes; P, peroxisome; PM, plasma membrane; U, ubiquitous; 
V, vacuoles; +, positive findings; −, negative findings.
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(121). It has been shown that antibodies are most important in 
this type of diseases and that these antibodies can lead to altera-
tion of cellular function with consequences on behavior (104, 
133, 134) or tissue destruction by complement (108). There is a 
requirement for these antibodies to access the CNS in order to 
be of disease relevance (135). Recently, a strong influence of a 
specific HLA haplotype has been shown in anti-LGI1 encephalitis 
in Koreans (136). So far, the role of T cells has not been assessed 
in detail in these illnesses but deserves much more attention 
in future efforts. These diseases are treated by immunotherapy 
(132, 137). In cases in which the origin is paraneoplastic, the 
neoplasm needs to be treated in addition to immunotherapy.
Paraneoplastic Disease of the CnS
Why is there such a preference of paraneoplastic CNS disorders 
for neuronal antigens? Why are there no or only few cases of 
paraneoplastic MS or NMOSD? Possibly the answer lies in 
the antigen repertoires that are preferentially displayed by 
neoplasms. In NMOSD, cases with paraneoplastic origin have 
been reported (138, 139). In addition, certain brain neoplasms 
might result in paraneoplastic cases of MS even though such 
cases have not been interpreted as paraneoplastic diseases so far 
but rather in the opposite way that the molecular changes in the 
MS lesion have led to development of the neoplasms (140–142). 
As discussed in the section regarding HLA haplotypes, the 
FiGURe 1 | Schematic representation of the major histocompatibility 
complex (MHC)/human leukocyte antigen (HLA) haplotype and 
additional factors on disease breakthrough in autoimmune or/and 
paraneoplastic diseases.
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density of the presented disease-inducing antigen expressed by 
the neoplasms is potentially an important factor that can lead 
to paraneoplastic disease. Therefore, a higher density of the 
presented autoantigen would possibly more likely lead to disease 
induction.
THeRAPeUTiC COnSiDeRATiOnS
Since the adaptive immune response is of such great relevance 
in various immunologically mediated disorder of the CNS it is 
obvious that it should be targeted to halt and possibly cure auto-
immune and paraneoplastic diseases of the CNS. Of course, in 
paraneoplastic diseases always the underlying malignancy should 
be treated by surgical, radiotherapeutic, and chemotherapeutic 
approaches, since the eradication of the malignancy with pres-
ence of the antigens that drive the disease can possibly lead to an 
improvement of the paraneoplastic disease condition affecting the 
CNS. It has been proposed that immunotherapeutic approaches 
should mainly affect the humoral immune response, since the 
cellular immune response by CD8+ T cells is of great importance 
in tumor rejection (143). This aspect needs to be investigated in 
more depth.
In autoimmune diseases of CNS depending on the dominance 
of the T or/and B  cell response, a rational treatment approach 
should be used. In most diseases in which autoantibodies are of 
major importance, the depletion of B cells by rituximab a mono-
clonal antibody (mAb) that targets CD20 has been shown to be of 
great efficacy (144–146). This is the case for AE with membrane 
molecules as target antigens of the immune response (132, 137, 
146). In NMOSD, depletion of B cells is well established as a very 
efficacious treatment approach (145). Also in MS, depletion of 
B cells has been shown to be of great therapeutic efficacy (144). 
This has been underscored by recent data with ocrelizumab a 
novel human mAb also targeting CD20 (147, 148). Since B cells 
are very potent professional antigen-presenting cells, the deple-
tion of such cells leads also to reduced presentation of antigens 
to T cells (1, 149, 150). This reduction of antigen presentation in 
individuals that have been treated with B cell depleting agents is 
potentially one of the most important immunotherapeutic effects 
of such a therapeutic approach.
In MS, it has been demonstrated that decreasing numbers 
of T cells that enter the CNS can result in reduction of contrast 
enhancing lesions, numbers of new lesions, and improvement of 
clinical disease score as well (3). Also, modulating T cell responses 
regarding the way how these cells react in expression of certain 
immune mediators can affect disease.
The combined depletion of T and B  cells by alemtuzumab 
by targeting CD52 has been shown to be very efficacious in 
MS (151–153). In a retrospective case series in NMOSD, this 
approach failed to be effective (154). The reasons are not clear so 
far, but the authors recommend caution. The approach has not 
been used in AE so far. This restricted use is most likely because 
potential side effects are dreaded. Nevertheless, such a therapeutic 
approach embodies a great potential for cure in selected patient 
populations.
Another approach to affect autoimmune and paraneoplastic 
diseases would be the blockade of the terminal phase of inflam-
mation which is partially mediated by antibodies and that leads 
to tissue destruction. In this aspect, the use of eculizumab, a 
mAb depleting the complement factor C5 holds great promise. 
There are trials ongoing in NMOSD that investigate the efficacy 
of eculizumab in disease arrest. Initial observations are very 
promising (155). The use of complement inhibitors could be of 
great therapeutic potential in MS as well as in certain types of AE 
in which complement is strongly involved in pathophysiology. 
So far, the use of eculizumab is restricted due to limited clinical 
development efforts because of its high cost.
COnCLUSiOn
There is a great similarity in immune mechanisms of different 
autoimmune and paraneoplastic diseases of the CNS (Figure 1). 
The adaptive immunity seems to be the main driver of selected 
organ pathology in autoimmune and paraneoplastic diseases. 
Specific HLA haplotypes are associated with different autoim-
mune and paraneoplastic autoimmune disorders. HLA haplo-
types predispose for selection of certain autoantigens that drive 
such diseases. The phenotype of autoimmune and paraneoplastic 
diseases of the CNS differs depending on the antigens that drive 
the immune responses. Neoantigens can possibly contribute to 
the development of these disorders. The pivotal role of the adap-
tive immunity in autoimmune and paraneoplastic diseases of the 
CNS allows directed immune interventions to modulate T and 
B cell responses.
AUTHOR COnTRiBUTiOnS
RW outlined the subject of the review; searched for, analyzed, and 
interpreted the literature; wrote the manuscript, and agreed to be 
accountable for all aspects of the work.
6Weissert CNS Autoimmune and Paraneoplastic Disorders
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 336
ReFeRenCeS
1. Riedhammer C, Weissert R. Antigen presentation, autoantigens, and 
immune regulation in multiple sclerosis and other autoimmune diseases. 
Front Immunol (2015) 6:322. doi:10.3389/fimmu.2015.00322 
2. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of 
paraneoplastic autoimmunity. Clin Rev Allerg Immunol (2012) 42(2):135–44. 
doi:10.1007/s12016-010-8248-5 
3. Weissert R. The immune pathogenesis of multiple sclerosis. J Neuroimmune 
Pharmacol (2013) 8(4):857–66. doi:10.1007/s11481-013-9467-3 
4. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated 
autoimmunity: viral peptides activate human T  cell clones specific for 
myelin basic protein. Cell (1995) 80(5):695–705. doi:10.1016/0092-8674(95) 
90348-8 
5. Weissert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, 
et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. 
J Clin Invest (1998) 102(6):1265–73. doi:10.1172/JCI3022 
6. Posner JB. Pathogenesis of central nervous system paraneoplastic syndromes. 
Rev Neurol (Paris) (1992) 148(6–7):502–12. 
7. Weissert R, de Graaf KL, Storch MK, Barth S, Linington C, Lassmann H, 
et  al. MHC class II-regulated central nervous system autoaggression and 
T  cell responses in peripheral lymphoid tissues are dissociated in myelin 
oligodendrocyte glycoprotein-induced experimental autoimmune enceph-
alomyelitis. J Immunol (2001) 166(12):7588–99. doi:10.4049/jimmunol.166. 
12.7588 
8. de Graaf KL, Albert M, Weissert R. Autoantigen conformation influences 
both B- and T-cell responses and encephalitogenicity. J Biol Chem (2012) 
287(21):17206–13. doi:10.1074/jbc.M111.304246 
9. Dalmau J. NMDA receptor encephalitis and other antibody-mediated 
disorders of the synapse: the 2016 Cotzias Lecture. Neurology (2016) 
87(23):2471–82. doi:10.1212/WNL.0000000000003414 
10. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selec-
tion events during affinity maturation. Science (2007) 315(5811):528–31. 
doi:10.1126/science.1136736 
11. Weinstein JS, Hernandez SG, Craft J. T  cells that promote B-Cell matu-
ration in systemic autoimmunity. Immunol Rev (2012) 247(1):160–71. 
doi:10.1111/j.1600-065X.2012.01122.x 
12. Shlomchik MJ. Activating systemic autoimmunity: B’s, T’s, and tolls. Curr 
Opin Immunol (2009) 21(6):626–33. doi:10.1016/j.coi.2009.08.005 
13. Claes N, Fraussen J, Stinissen P, Hupperts R, Somers V. B  cells are multi-
functional players in multiple sclerosis pathogenesis: insights from thera-
peutic interventions. Front Immunol (2015) 6:642. doi:10.3389/fimmu.2015. 
00642 
14. von Budingen HC, Bar-Or A, Zamvil SS. B  cells in multiple sclerosis: 
connecting the dots. Curr Opin Immunol (2011) 23(6):713–20. doi:10.1016/ 
j.coi.2011.09.003 
15. Richard-Miceli C, Criswell LA. Emerging patterns of genetic overlap across 
autoimmune disorders. Genome Med (2012) 4(1):6. doi:10.1186/gm305 
16. Tadaki H, Saitsu H, Nishimura-Tadaki A, Imagawa T, Kikuchi M, Hara 
R, et  al. De novo 19q13.42 duplications involving NLRP gene cluster in a 
patient with systemic-onset juvenile idiopathic arthritis. J Hum Genet (2011) 
56(5):343–7. doi:10.1038/jhg.2011.16 
17. International Multiple Sclerosis Genetics Consortium, Wellcome Trust 
Case Control Consortium, Sawcer S, Hellenthal G, Pirinen M, Spencer 
CC, et al. Genetic risk and a primary role for cell-mediated immune mech-
anisms in multiple sclerosis. Nature (2011) 476(7359):214–9. doi:10.1038/ 
nature10251 
18. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-
microarray analysis of multiple sclerosis lesions yields new targets validated 
in autoimmune encephalomyelitis. Nat Med (2002) 8(5):500–8. doi:10.1038/
nm0502-500 
19. Herrmann MM, Barth S, Greve B, Schumann KM, Bartels A, Weissert R. 
Identification of gene expression patterns crucially involved in experimental 
autoimmune encephalomyelitis and multiple sclerosis. Dis Model Mech 
(2016) 9(10):1211–20. doi:10.1242/dmm.025536 
20. Ince-Dunn G, Okano HJ, Jensen KB, Park WY, Zhong R, Ule J, et al. Neuronal 
Elav-like (Hu) proteins regulate RNA splicing and abundance to control 
glutamate levels and neuronal excitability. Neuron (2012) 75(6):1067–80. 
doi:10.1016/j.neuron.2012.07.009 
21. Hathaway CK, Chang AS, Grant R, Kim HS, Madden VJ, Bagnell CR Jr, 
et al. High Elmo1 expression aggravates and low Elmo1 expression prevents 
diabetic nephropathy. Proc Natl Acad Sci U S A (2016) 113(8):2218–22. 
doi:10.1073/pnas.1600511113 
22. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, et al. Epigenome-wide 
differences in pathology-free regions of multiple sclerosis-affected brains. 
Nat Neurosci (2014) 17(1):121–30. doi:10.1038/nn.3588 
23. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, 
et  al. SOX2 controls tumour initiation and cancer stem-cell functions in 
squamous-cell carcinoma. Nature (2014) 511(7508):246–50. doi:10.1038/
nature13305 
24. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle 
and environmental risk factors for multiple sclerosis. Nat Rev Neurol (2017) 
13(1):25–36. doi:10.1038/nrneurol.2016.187 
25. Becklund BR, Severson KS, Vang SV, DeLuca HF. UV radiation suppresses 
experimental autoimmune encephalomyelitis independent of vitamin D 
production. Proc Natl Acad Sci U S A (2010) 107(14):6418–23. doi:10.1073/
pnas.1001119107 
26. Rhead B, Baarnhielm M, Gianfrancesco M, Mok A, Shao X, Quach H, 
et  al. Mendelian randomization shows a causal effect of low vitamin D 
on multiple sclerosis risk. Neurol Genet (2016) 2(5):e97. doi:10.1212/
NXG.0000000000000097 
27. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure 
influences risk of multiple sclerosis in monozygotic twins. Neurology (2007) 
69(4):381–8. doi:10.1212/01.wnl.0000268266.50850.48 
28. Min JH, Waters P, Vincent A, Cho HJ, Joo BE, Woo SY, et  al. Low levels 
of vitamin D in neuromyelitis optica spectrum disorder: association with 
disease disability. PLoS One (2014) 9(9):e107274. doi:10.1371/journal.pone. 
0107274 
29. Hedstrom AK, Sundqvist E, Baarnhielm M, Nordin N, Hillert J, Kockum I, 
et al. Smoking and two human leukocyte antigen genes interact to increase 
the risk for multiple sclerosis. Brain (2011) 134(Pt 3):653–64. doi:10.1093/
brain/awq371 
30. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, 
but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 
(2009) 73(9):696–701. doi:10.1212/WNL.0b013e3181b59c40 
31. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MM, et al. Multiple 
sclerosis patients have a distinct gut microbiota compared to healthy controls. 
Sci Rep (2016) 6:28484. doi:10.1038/srep28484 
32. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the 
human gut microbiome in multiple sclerosis. Nat Commun (2016) 7:12015. 
doi:10.1038/ncomms12015 
33. Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS. Gut 
microbiome analysis in neuromyelitis optica reveals overabundance of 
Clostridium perfringens. Ann Neurol (2016) 80(3):443–7. doi:10.1002/ 
ana.24718 
34. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, et  al. 
Commensal microbiota and myelin autoantigen cooperate to trigger 
autoimmune demyelination. Nature (2011) 479(7374):538–41. doi:10.1038/
nature10554 
35. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek 
MJ, et  al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a 
prospective study. JAMA (2001) 286(24):3083–8. doi:10.1001/jama.286. 
24.3083 
36. Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A. Primary infection 
with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol (2010) 
67(6):824–30. doi:10.1002/ana.21978 
37. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, 
et  al. Epstein–Barr virus infection is not a characteristic feature of multi-
ple sclerosis brain. Brain (2009) 132(Pt 12):3318–28. doi:10.1093/brain/ 
awp200 
38. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, 
et  al. Sodium chloride drives autoimmune disease by the induction of 
pathogenic TH17 cells. Nature (2013) 496(7446):518–22. doi:10.1038/ 
nature11868 
39. Nourbakhsh B, Graves J, Casper TC, Lulu S, Waldman A, Belman A, et al. 
Dietary salt intake and time to relapse in paediatric multiple sclerosis. 
J Neurol Neurosurg Psychiatry (2016) 87(12):1350–3. doi:10.1136/jnnp-2016- 
313410 
7Weissert CNS Autoimmune and Paraneoplastic Disorders
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 336
40. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med (2000) 
343(10):702–9. doi:10.1056/NEJM200009073431006 
41. Martel P, Loiseau P, Joly P, Busson M, Lepage V, Mouquet H, et al. Paraneoplastic 
pemphigus is associated with the DRB1*03 allele. J Autoimmun (2003) 
20(1):91–5. doi:10.1016/S0896-8411(02)00092-6 
42. Segurado OG, Arnaiz-Villena A, Wank R, Schendel DJ. The multifactorial 
nature of MHC-linked susceptibility to insulin-dependent diabetes. 
Autoimmunity (1993) 15(1):85–9. doi:10.3109/08916939309004844 
43. Abraham RS, Kudva YC, Wilson SB, Strominger JL, David CS. Co-expression 
of HLA DR3 and DQ8 results in the development of spontaneous insulitis and 
loss of tolerance to GAD65 in transgenic mice. Diabetes (2000) 49(4):548–54. 
doi:10.2337/diabetes.49.4.548 
44. Murray JS, Madri J, Tite J, Carding SR, Bottomly K. MHC control of CD4+ 
T  cell subset activation. J Exp Med (1989) 170(6):2135–40. doi:10.1084/
jem.170.6.2135 
45. MacDonald HR, Lees RK, Schneider R, Zinkernagel RM, Hengartner H. 
Positive selection of CD4+ thymocytes controlled by MHC class II gene 
products. Nature (1988) 336(6198):471–3. doi:10.1038/336471a0 
46. Kappler J, Kotzin B, Herron L, Gelfand EW, Bigler RD, Boylston A, et al. V 
beta-specific stimulation of human T cells by staphylococcal toxins. Science 
(1989) 244(4906):811–3. doi:10.1126/science.2524876 
47. Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY. Positive 
and negative selection of an antigen receptor on T cells in transgenic mice. 
Nature (1988) 336(6194):73–6. doi:10.1038/336073a0 
48. Hengartner H, Odermatt B, Schneider R, Schreyer M, Walle G, MacDonald 
HR, et  al. Deletion of self-reactive T  cells before entry into the thymus 
medulla. Nature (1988) 336(6197):388–90. doi:10.1038/336388a0 
49. Gascoigne NR, Rybakin V, Acuto O, Brzostek J. TCR signal strength and 
T cell development. Annu Rev Cell Dev Biol (2016) 32:327–48. doi:10.1146/
annurev-cellbio-111315-125324 
50. Kincaid EZ, Murata S, Tanaka K, Rock KL. Specialized proteasome subunits 
have an essential role in the thymic selection of CD8(+) T cells. Nat Immunol 
(2016) 17(8):938–45. doi:10.1038/ni.3480 
51. Gulwani-Akolkar B, Posnett DN, Janson CH, Grunewald J, Wigzell H, 
Akolkar P, et al. T cell receptor V-segment frequencies in peripheral blood 
T  cells correlate with human leukocyte antigen type. J Exp Med (1991) 
174(5):1139–46. doi:10.1084/jem.174.5.1139 
52. Akolkar PN, Gulwani-Akolkar B, Pergolizzi R, Bigler RD, Silver J. Influence 
of HLA genes on T cell receptor V segment frequencies and expression levels 
in peripheral blood lymphocytes. J Immunol (1993) 150(7):2761–73. 
53. Moudgil KD, Sercarz EE. Dominant determinants in hen eggwhite lysozyme 
correspond to the cryptic determinants within its self-homologue, mouse 
lysozyme: implications in shaping of the T cell repertoire and autoimmunity. 
J Exp Med (1993) 178(6):2131–8. doi:10.1084/jem.178.6.2131 
54. Morgan DJ, Nugent CT, Raveney BJ, Sherman LA. In a transgenic model of 
spontaneous autoimmune diabetes, expression of a protective class II MHC 
molecule results in thymic deletion of diabetogenic CD8+ T cells. J Immunol 
(2004) 172(2):1000–8. doi:10.4049/jimmunol.172.2.1000 
55. Weissert R, editor. Experimental autoimmune encephalomyelitis. Models, 
Disease Biology and Experimental Therapy. Rijeka: In Tech (2012). p. 1–19.
56. Gaertner S, de Graaf KL, Olsson T, Weissert R. Immunogenicity of Torpedo 
acetylcholine receptor in the context of different rat MHC class II haplotypes 
and non-MHC genomes. Immunogenetics (2004) 56(1):61–4. doi:10.1007/
s00251-004-0656-3 
57. Gaertner S, de Graaf KL, Wienhold W, Wiesmuller KH, Melms A, Weissert 
R. Lack of pathogenicity of immunodominant T and B cell determinants of 
the nicotinic acetylcholine receptor epsilon-chain. J Neuroimmunol (2004) 
152(1–2):44–56. doi:10.1016/j.jneuroim.2004.03.019 
58. de Graaf KL, Berne GP, Herrmann MM, Hansson GK, Olsson T, Weissert 
R. CDR3 sequence preference of TCRBV8S2+ T cells within the CNS does 
not reflect single amino acid dependent avidity expansion. J Neuroimmunol 
(2005) 166(1–2):47–54. doi:10.1016/j.jneuroim.2005.05.004 
59. Mangalam AK, Taneja V, David CS. HLA class II molecules influence 
susceptibility versus protection in inflammatory diseases by determining 
the cytokine profile. J Immunol (2013) 190(2):513–8. doi:10.4049/jimmunol. 
1201891 
60. Tuncel J, Haag S, Holmdahl R. MHC class II alleles associated with Th1 rather 
than Th17 type immunity drive the onset of early arthritis in a rat model of 
rheumatoid arthritis. Eur J Immunol (2016). doi:10.1002/eji.201646760 
61. Lambe T, Leung JC, Bouriez-Jones T, Silver K, Makinen K, Crockford 
TL, et  al. CD4 T  cell-dependent autoimmunity against a melanocyte 
neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand 
interactions. J Immunol (2006) 177(5):3055–62. doi:10.4049/jimmunol.177. 
5.3055 
62. Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, et al. A large fraction 
of HLA class I ligands are proteasome-generated spliced peptides. Science 
(2016) 354(6310):354–8. doi:10.1126/science.aaf4384 
63. Anderton SM. Post-translational modifications of self antigens: implications 
for autoimmunity. Curr Opin Immunol (2004) 16(6):753–8. doi:10.1016/j.
coi.2004.09.001 
64. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl 
R. Humoral immune response to citrullinated collagen type II determi-
nants in early rheumatoid arthritis. Eur J Immunol (2005) 35(5):1643–52. 
doi:10.1002/eji.200526000 
65. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom 
A, et al. Structure and pathogenicity of antibodies specific for citrullinated 
collagen type II in experimental arthritis. J Exp Med (2009) 206(2):449–62. 
doi:10.1084/jem.20081862 
66. Carrillo-Vico A, Leech MD, Anderton SM. Contribution of myelin autoan-
tigen citrullination to T cell autoaggression in the central nervous system. 
J Immunol (2010) 184(6):2839–46. doi:10.4049/jimmunol.0903639 
67. Bradford CM, Ramos I, Cross AK, Haddock G, McQuaid S, Nicholas AP, et al. 
Localisation of citrullinated proteins in normal appearing white matter and 
lesions in the central nervous system in multiple sclerosis. J Neuroimmunol 
(2014) 273(1–2):85–95. doi:10.1016/j.jneuroim.2014.05.007 
68. Jin N, Wang Y, Crawford F, White J, Marrack P, Dai S, et  al. N-terminal 
additions to the WE14 peptide of chromogranin A create strong autoantigen 
agonists in type 1 diabetes. Proc Natl Acad Sci U S A (2015) 112(43):13318–23. 
doi:10.1073/pnas.1517862112 
69. Backlund J, Treschow A, Bockermann R, Holm B, Holm L, Issazadeh-
Navikas S, et  al. Glycosylation of type II collagen is of major 
importance for T  cell tolerance and pathology in collagen-induced 
arthritis. Eur J Immunol (2002) 32(12):3776–84. doi:10.1002/1521-4141 
(200212)32:12<3776::AID-IMMU3776>3.0.CO;2-A 
70. Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, et  al. Novel 
conformation of histidyl-transfer RNA synthetase in the lung: the target 
tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum (2007) 
56(8):2729–39. doi:10.1002/art.22790 
71. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et  al. 
Encephalitogenic potential of the myelin basic protein peptide (amino 
acids 83-99) in multiple sclerosis: results of a phase II clinical trial with 
an altered peptide ligand. Nat Med (2000) 6(10):1167–75. doi:10.1038/ 
80516 
72. Riedhammer C, Halbritter D, Weissert R. Increased immune reactivity to 
central nervous system-derived naturally presented peptides in patients with 
active multiple sclerosis. J Allergy Clin Immunol (2017) 139(2):694–6.e7. 
doi:10.1016/j.jaci.2016.08.015 
73. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann 
H. Multiple sclerosis: in  situ evidence for antibody- and complement-me-
diated demyelination. Ann Neurol (1998) 43(4):465–71. doi:10.1002/ana. 
410430409 
74. Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. 
Acta Neuropathol (2017) 133(2):223–44. doi:10.1007/s00401-016-1631-4
75. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, 
et  al. Age-dependent B  cell autoimmunity to a myelin surface antigen in 
pediatric multiple sclerosis. J Immunol (2009) 183(6):4067–76. doi:10.4049/
jimmunol.0801888 
76. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-
Nun A, et al. Myelin-specific T cells also recognize neuronal autoantigen in a 
transgenic mouse model of multiple sclerosis. Nat Med (2009) 15(6):626–32. 
doi:10.1038/nm.1975 
77. Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, 
et  al. Naturally presented peptides on major histocompatibility complex I 
and II molecules eluted from central nervous system of multiple sclerosis 
patients. Mol Cell Proteomics (2009) 8(9):2090–101. doi:10.1074/mcp.
M900001-MCP200 
78. Muraro PA, Kalbus M, Afshar G, McFarland HF, Martin R. T cell response 
to 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) in multiple 
8Weissert CNS Autoimmune and Paraneoplastic Disorders
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 336
sclerosis patients. J Neuroimmunol (2002) 130(1–2):233–42. doi:10.1016/
S0165-5728(02)00229-1 
79. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, et al. 
Antigen microarrays identify unique serum autoantibody signatures in 
clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S 
A (2008) 105(48):18889–94. doi:10.1073/pnas.0806310105 
80. Terryberry JW, Thor G, Peter JB. Autoantibodies in neurodegenerative dis-
eases: antigen-specific frequencies and intrathecal analysis. Neurobiol Aging 
(1998) 19(3):205–16. doi:10.1016/S0197-4580(98)00049-9 
81. Andersson M, Yu M, Soderstrom M, Weerth S, Baig S, Solders G, et  al. 
Multiple MAG peptides are recognized by circulating T and B lymphocytes 
in polyneuropathy and multiple sclerosis. Eur J Neurol (2002) 9(3):243–51. 
doi:10.1046/j.1468-1331.2002.00391.x 
82. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. 
Expansion and functional relevance of high-avidity myelin-specific CD4+ 
T cells in multiple sclerosis. J Immunol (2004) 172(6):3893–904. doi:10.4049/
jimmunol.172.6.3893 
83. Olsson T, Sun J, Hillert J, Hojeberg B, Ekre HP, Andersson G, et al. Increased 
numbers of T  cells recognizing multiple myelin basic protein epitopes 
in multiple sclerosis. Eur J Immunol (1992) 22(4):1083–7. doi:10.1002/
eji.1830220431 
84. de Rosbo NK, Kaye JF, Eisenstein M, Mendel I, Hoeftberger R, Lassmann 
H, et  al. The myelin-associated oligodendrocytic basic protein region 
MOBP15-36 encompasses the immunodominant major encephalitogenic 
epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-as-
sociated HLA-DRB1*1501. J Immunol (2004) 173(2):1426–35. doi:10.4049/
jimmunol.173.2.1426 
85. Wallstrom E, Khademi M, Andersson M, Weissert R, Linington C, 
Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein 
peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur 
J Immunol (1998) 28(10):3329–35. doi:10.1002/(SICI)1521-4141(199810) 
28:10<3329::AID-IMMU3329>3.3.CO;2-2 
86. Weissert R, Kuhle J, de Graaf KL, Wienhold W, Herrmann MM, Muller C, 
et al. High immunogenicity of intracellular myelin oligodendrocyte glyco-
protein epitopes. J Immunol (2002) 169(1):548–56. doi:10.4049/jimmunol. 
169.1.548 
87. Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, 
et  al. Antibodies to MOG are transient in childhood acute dissemi-
nated encephalomyelitis. Neurology (2011) 77(6):580–8. doi:10.1212/
WNL.0b013e318228c0b1 
88. Johns TG, Bernard CC. Binding of complement component Clq to 
myelin oligodendrocyte glycoprotein: a novel mechanism for regulating 
CNS inflammation. Mol Immunol (1997) 34(1):33–8. doi:10.1016/
S0161-5890(97)00005-9 
89. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pit’ha J. Elevated 
intrathecal antibodies against the medium neurofilament subunit in 
multiple sclerosis. J Neurol (2007) 254(1):20–5. doi:10.1007/s00415-006- 
0185-0 
90. Trotter JL, Hickey WF, van der Veen RC, Sulze L. Peripheral blood 
mononuclear cells from multiple sclerosis patients recognize myelin prote-
olipid protein and selected peptides. J Neuroimmunol (1991) 33(1):55–62. 
doi:10.1016/0165-5728(91)90034-5 
91. Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H, 
et al. Multiple sclerosis: comparison of the human T-cell response to S100 
beta and myelin basic protein reveals parallels to rat experimental autoim-
mune panencephalitis. Brain (1997) 120(Pt 8):1437–45. doi:10.1093/brain/ 
120.8.1437 
92. Banki K, Colombo E, Sia F, Halladay D, Mattson DH, Tatum AH, et  al. 
Oligodendrocyte-specific expression and autoantigenicity of transaldolase 
in multiple sclerosis. J Exp Med (1994) 180(5):1649–63. doi:10.1084/
jem.180.5.1649 
93. Colombo E, Banki K, Tatum AH, Daucher J, Ferrante P, Murray RS, et al. 
Comparative analysis of antibody and cell-mediated autoimmunity to tran-
saldolase and myelin basic protein in patients with multiple sclerosis. J Clin 
Invest (1997) 99(6):1238–50. doi:10.1172/JCI119281 
94. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, 
Cree BA, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit 
a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol (2012) 
72(1):53–64. doi:10.1002/ana.23651 
95. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara 
K, et al. A serum autoantibody marker of neuromyelitis optica: distinction 
from multiple sclerosis. Lancet (2004) 364(9451):2106–12. doi:10.1016/
S0140-6736(04)17551-X 
96. Bruck W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, 
et al. Neuromyelitis optica lesions may inform multiple sclerosis heterogene-
ity debate. Ann Neurol (2012) 72(3):385–94. doi:10.1002/ana.23621 
97. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, 
Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 
antibody-positive NMO spectrum disorders. Neurology (2014) 82(6):474–81. 
doi:10.1212/WNL.0000000000000101 
98. Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugiere S, et  al. 
Characteristics in limbic encephalitis with anti-adenylate kinase 5 auto-
antibodies. Neurology (2017) 88(6):514–24. doi:10.1212/WNL.00000000 
00003586 
99. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et  al. AMPA 
receptor antibodies in limbic encephalitis alter synaptic receptor location. 
Ann Neurol (2009) 65(4):424–34. doi:10.1002/ana.21589 
100. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. 
Antiamphiphysin antibodies are associated with various paraneoplastic 
neurological syndromes and tumors. Arch Neurol (1999) 56(2):172–7. 
doi:10.1001/archneur.56.2.172 
101. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez 
E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuro-
myotonia. Ann Neurol (2011) 69(2):303–11. doi:10.1002/ana.22297 
102. Monstad SE, Nostbakken JK, Vedeler CA. CRMP5 antibodies found in a 
patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg 
Psychiatry (2009) 80(2):241–2. doi:10.1136/jnnp.2008.149336 
103. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with 
Hodgkin disease. An immunological study. Arch Neurol (1976) 33(9):660–1. 
doi:10.1001/archneur.1976.00500090066014 
104. Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et  al. 
Antibodies to surface dopamine-2 receptor in autoimmune movement and 
psychiatric disorders. Brain (2012) 135(Pt 11):3453–68. doi:10.1093/brain/ 
aws256 
105. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, 
et  al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, 
a subunit of Kv4.2 potassium channels. Ann Neurol (2013) 73(1):120–8. 
doi:10.1002/ana.23756 
106. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. 
Encephalitis with refractory seizures, status epilepticus, and antibodies to the 
GABAA receptor: a case series, characterisation of the antigen, and analysis 
of the effects of antibodies. Lancet Neurol (2014) 13(3):276–86. doi:10.1016/
S1474-4422(13)70299-0 
107. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et  al. 
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case 
series and characterisation of the antigen. Lancet Neurol (2010) 9(1):67–76. 
doi:10.1016/S1474-4422(09)70324-2 
108. Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, et  al. 
Immunopathology of autoantibody-associated encephalitides: clues 
for pathogenesis. Brain (2012) 135(Pt 5):1622–38. doi:10.1093/brain/ 
aws082 
109. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, et  al. Higher auto-
antibody levels and recognition of a linear NH2-terminal epitope in the 
autoantigen GAD65, distinguish stiff-man syndrome from insulin-depen-
dent diabetes mellitus. J Exp Med (1994) 180(2):595–606. doi:10.1084/jem. 
180.2.595 
110. Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint 
B, et al. Glycine receptor antibodies in PERM and related syndromes: char-
acteristics, clinical features and outcomes. Brain (2014) 137(Pt 8):2178–92. 
doi:10.1093/brain/awu142 
111. Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. 
Cytotoxic T  cell activity against peptides of Hu protein in anti-Hu syn-
drome. J Neurol Sci (2002) 201(1–2):9–12. doi:10.1016/S0022-510X(02) 
00157-0 
112. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated para-
neoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 
patients. Medicine (1992) 71(2):59–72. doi:10.1097/00005792-199203000- 
00001 
9Weissert CNS Autoimmune and Paraneoplastic Disorders
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 336
113. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A 
novel non-rapid-eye movement and rapid-eye-movement parasomnia with 
sleep breathing disorder associated with antibodies to IgLON5: a case series, 
characterisation of the antigen, and post-mortem study. Lancet Neurol (2014) 
13(6):575–86. doi:10.1016/S1474-4422(14)70051-1 
114. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et  al. 
Potassium channel antibody-associated encephalopathy: a potentially 
immunotherapy-responsive form of limbic encephalitis. Brain (2004) 127(Pt 
3):701–12. doi:10.1093/brain/awh077 
115. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, 
et al. Investigation of LGI1 as the antigen in limbic encephalitis previously 
attributed to potassium channels: a case series. Lancet Neurol (2010) 
9(8):776–85. doi:10.1016/S1474-4422(10)70137-X 
116. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. 
Ma1, a novel neuron- and testis-specific protein, is recognized by the serum 
of patients with paraneoplastic neurological disorders. Brain (1999) 122(Pt 
1):27–39. doi:10.1093/brain/122.1.27 
117. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. 
Clinical analysis of anti-Ma2-associated encephalitis. Brain (2004) 127(Pt 
8):1831–44. doi:10.1093/brain/awh203 
118. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma 
D, et  al. Paraneoplastic cerebellar ataxia due to autoantibodies against 
a glutamate receptor. N Engl J Med (2000) 342(1):21–7. doi:10.1056/
NEJM200001063420104 
119. Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, 
Antoine JC, et  al. Antibodies to metabotropic glutamate receptor 5 in 
the Ophelia syndrome. Neurology (2011) 77(18):1698–701. doi:10.1212/
WNL.0b013e3182364a44 
120. Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Kawachi I, Katada S, Glaser 
CA, et al. Human neurexin-3alpha antibodies associate with encephalitis and 
alter synapse development. Neurology (2016) 86(24):2235–42. doi:10.1212/
WNL.0000000000002775 
121. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et  al. 
Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated 
with ovarian teratoma. Ann Neurol (2007) 61(1):25–36. doi:10.1002/
ana.21050 
122. Hiasa Y, Kunishige M, Mitsui T, Kondo S, Kuriwaka R, Shigekiyo S, et  al. 
Complicated paraneoplastic neurological syndromes: a report of two patients 
with small cell or non-small cell lung cancer. Clin Neurol Neurosurg (2003) 
106(1):47–9. doi:10.1016/S0303-8467(03)00059-3 
123. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold 
SC Jr, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus 
and breast cancer. Ann Neurol (1991) 29(3):241–51. doi:10.1002/ana. 
410290303 
124. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients 
with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann 
Neurol (1983) 14(6):609–13. doi:10.1002/ana.410140603 
125. Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. 
Autoimmune response of patients with paraneoplastic cerebellar degen-
eration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 
18(5):592–600. doi:10.1002/ana.410180513 
126. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies 
to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. 
Neurology (2004) 62(5):778–82. doi:10.1212/01.WNL.0000113749.77217.01 
127. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of 
optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp 
Med (2005) 202(4):473–7. doi:10.1084/jem.20050304 
128. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et  al. 
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuro-
myelitis optica phenotype. Neurology (2012) 79(12):1273–7. doi:10.1212/
WNL.0b013e31826aac4e 
129. Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica 
pathology produced in naive rats by intracerebral administration of 
NMO-IgG. Acta Neuropathol (2014) 127(4):539–51. doi:10.1007/s00401- 
013-1204-8 
130. Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-
dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein 
assembly in orthogonal arrays. J Biol Chem (2012) 287(17):13829–39. 
doi:10.1074/jbc.M112.344325 
131. McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology 
and mechanisms. Acta Neuropathol (2011) 122(4):381–400. doi:10.1007/
s00401-011-0876-1 
132. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical 
approach to diagnosis of autoimmune encephalitis. Lancet Neurol (2016) 
15(4):391–404. doi:10.1016/S1474-4422(15)00401-9 
133. Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia 
E, Aguilar E, et al. Human N-methyl d-aspartate receptor antibodies alter 
memory and behaviour in mice. Brain (2015) 138(Pt 1):94–109. doi:10.1093/
brain/awu310 
134. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon 
RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-d-as-
partate receptor encephalitis. Ann Neurol (2014) 76(1):108–19. doi:10.1002/ 
ana.24195 
135. Castillo-Gomez E, Kastner A, Steiner J, Schneider A, Hettling B, Poggi G, 
et  al. The brain as immunoprecipitator of serum autoantibodies against 
N-methyl-d-aspartate receptor subunit NR1. Ann Neurol (2016) 79(1):144–
51. doi:10.1002/ana.24545 
136. Kim TJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et  al. Anti-LGI1 
encephalitis is associated with unique HLA subtypes. Ann Neurol (2017) 
81(2):183–92. doi:10.1002/ana.24860 
137. Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune enceph-
alopathies and immunotherapies. Neurotherapeutics (2016) 13(1):147–62. 
doi:10.1007/s13311-015-0410-6 
138. De Santis G, Caniatti L, De Vito A, De Gennaro R, Granieri E, Tola MR. 
A possible paraneoplastic neuromyelitis optica associated with lung cancer. 
Neurol Sci (2009) 30(5):397–400. doi:10.1007/s10072-009-0112-0 
139. Al-Harbi T, Al-Sarawi A, Binfalah M, Dermime S. Paraneoplastic neu-
romyelitis optica spectrum disorder associated with stomach carcinoid 
tumor. Hematol Oncol Stem Cell Ther (2014) 7(3):116–9. doi:10.1016/j.
hemonc.2014.06.001 
140. Reagan TJ, Freiman IS. Multiple cerebral gliomas in multiple sclerosis. 
J Neurol Neurosurg Psychiatry (1973) 36(4):523–8. doi:10.1136/jnnp. 
36.4.523 
141. Currie S, Urich H. Concurrence of multiple sclerosis and glioma. 
J Neurol Neurosurg Psychiatry (1974) 37(5):598–605. doi:10.1136/jnnp. 
37.5.598 
142. Paydarfar D, de la Monte SM. Case records of the Massachusetts General 
Hospital. Weekly clinicopathological exercises. Case 12-1997. A 50-year-old 
woman with multiple sclerosis and an enlarging frontal-lobe mass. N Engl 
J Med (1997) 336(16):1163–71. doi:10.1056/NEJM199704173361608 
143. Blachere NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M, et al. 
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection 
and trigger CNS autoimmunity with humoral activation. Eur J Immunol 
(2014) 44(11):3240–51. doi:10.1002/eji.201444624 
144. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl 
J Med (2008) 358(7):676–88. doi:10.1056/NEJMoa0706383 
145. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody 
to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 
131(Pt 11):3072–80. doi:10.1093/brain/awn240 
146. Ishiura H, Matsuda S, Higashihara M, Hasegawa M, Hida A, Hanajima 
R, et  al. Response of anti-NMDA receptor encephalitis without tumor to 
immunotherapy including rituximab. Neurology (2008) 71(23):1921–3. 
doi:10.1212/01.wnl.0000336648.43562.59 
147. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. 
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl 
J Med (2017) 376(3):221–34. doi:10.1056/NEJMoa1601277 
148. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. 
Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl 
J Med (2017) 376(3):209–20. doi:10.1056/NEJMoa1606468 
149. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod’homme 
T, Varrin-Doyer M, et al. MHC class II-dependent B cell APC function is 
required for induction of CNS autoimmunity independent of myelin-spe-
cific antibodies. J Exp Med (2013) 210(13):2921–37. doi:10.1084/jem. 
20130699 
150. Forsthuber TG, Shive CL, Wienhold W, de Graaf K, Spack EG, Sublett R, et al. 
T  cell epitopes of human myelin oligodendrocyte glycoprotein identified 
in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are 
10
Weissert CNS Autoimmune and Paraneoplastic Disorders
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 336
presented by human B cells. J Immunol (2001) 167(12):7119–25. doi:10.4049/
jimmunol.167.12.7119 
151. Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, 
et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl 
J Med (2008) 359(17):1786–801. doi:10.1056/NEJMoa0802670 
152. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. 
Alemtuzumab versus interferon beta 1a as first-line treatment for patients 
with relapsing-remitting multiple sclerosis: a randomised controlled phase 
3 trial. Lancet (2012) 380(9856):1819–28. doi:10.1016/S0140-6736(12) 
61769-3 
153. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, 
et al. Alemtuzumab for patients with relapsing multiple sclerosis after dis-
ease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 
380(9856):1829–39. doi:10.1016/S0140-6736(12)61768-1 
154. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in 
neuromyelitis optica spectrum disorders: a brief case series. J Neurol (2016) 
263(1):25–9. doi:10.1007/s00415-015-7925-y 
155. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker 
BG, Lucchinetti CF, et  al. Eculizumab in AQP4-IgG-positive 
relapsing neuromyelitis optica spectrum disorders: an open-label 
pilot study. Lancet Neurol (2013) 12(6):554–62. doi:10.1016/S1474- 
4422(13)70076-0 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Weissert. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the orig-
inal author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
